<DOC>
	<DOCNO>NCT02718755</DOCNO>
	<brief_summary>The goal clinical research study learn fludarabine , cytarabine ( ARA-C ) , erwinase ( also know asparaginase [ erwinia ] ) combination help control relapsed refractory hematologic malignancy . The safety drug also study .</brief_summary>
	<brief_title>Phase II Study Fludarabine , Cytarabine ( ARA-C ) Erwinase IV Patients With Relapsed Refractory Hematologic Malignancies</brief_title>
	<detailed_description>Study Drug Administration : Each cycle 28 day . If participant find eligible take part study , receive treatment 2 phase : Induction Consolidation . All participant receive dose level fludarabine , cytarabine , erwinase . If doctor think need , study drug dos may reduce . Induction Phase : Participant receive 1-2 cycle Induction phase . On Days 1-5 , participant receive fludarabine vein 30 minute cytarabine vein 2 hour . On Days 1-7 , participant receive erwinase vein 2 hour injection muscle . If disease respond Cycle 1 , participant may allow receive additional Induction cycle . If disease respond Induction , participant move Consolidation phase . Consolidation Phase : Participant receive 3 cycle Consolidation phase . On Days 1-4 , participant receive fludarabine vein 30 minute cytarabine vein 2 hour . If doctor think need , may reduce Days 1-3 . On Day 1 every day 15 day ( 3 , 5 , 7 ) , participant receive erwinase vein 2 hour injection muscle . Study Visits : On Day 1 ( Â± 3 day ) every cycle , participant physical exam . Induction Cycle ( ) : Every week , blood ( 2-3 teaspoon ) draw routine test . On Days 1 , 8 , 9 , 12 Cycle 1 : - Blood ( 1-2 teaspoon ) draw routine , biomarker , pharmacodynamic ( PD ) test . Biomarkers find blood/tissue may relate leukemia reacts study drug . PD test measure level study drug participant 's body may affect disease . - On Days 9 12 , blood ( 1-2 teaspoon ) draw pharmacokinetic ( PK ) test . PK test measure amount study drug body different time point . On Day 7 Cycle 1 , blood ( 1-2 teaspoon time ) drawn PK test dose 8 time next 24 hour dose . Some blood sample also use antibody test . Antibodies create immune system may attack foreign cell substance , study drug . On Day 21 Cycle 1 , participant bone marrow aspiration/biopsy biomarker PD test check status disease . If doctor think need , participant may additional bone marrow aspirations/biopsies study . If participant second Induction Cycle doctor think need , bone marrow aspirate/biopsy end second Induction Cycle biomarker PD test check status disease . Consolidation Cycles : Every 1-2 week , blood ( 2-3 teaspoon ) draw routine test . On Day 1 Cycle 1 , blood ( 1-2 teaspoon ) draw PK test dose 8 time next 24 hour dose . Some blood sample also use antibody test . If participant 2 induction cycle , end Cycle 1 Consolidation , doctor think need , bone marrow aspirate/biopsy biomarker PD test check status disease . Length Treatment : Participant may continue take study drug 3 cycle Consolidation Induction . Participant longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Patient 's participation study follow-up visit . Follow-Up Visits : Every 4-8 week participant 's last dose study drug , blood ( 2-3 teaspoon ) draw routine test . Every 6-12 month last dose study drug , study staff check participant . This either do phone regularly schedule clinic visit . If participant contact phone , phone call last 10 minute . This follow-up last participant withdraws study study end . Long-Term Follow-Up : After patient 's participation study , give option enroll long-term follow-up study ( DR09-0223 ) . Participant 's doctor explain detail , require sign separate consent form . This investigational study . Fludarabine cytarabine FDA approve commercially available treatment leukemia . Erwinase FDA approve commercially available use acute lymphoblastic leukemia . Its use study investigational . The combination drug investigational . The study doctor explain study drug design work . Up 20 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Patients diagnosis relapse refractory hematologic malignancy include , limited Acute myeloid leukemia ( AML ) , Acute lymphoblastic leukemia ( ALL ) , Burkitt 's leukemia/lymphoma , Prolymphocytic leukemia , Biphenotypic acute leukemia , Blastphase chronic myeloid leukemia ( CML ) , Bcell lymphoma , Richter 's transformation chronic lymphocytic leukemia ( CLL ) 2 . Age &lt; /= 60 year . 3 . Adequate organ function define : liver function ( bilirubin &lt; 2mg/dL , AST and/or ALT &lt; 2.5 x upper limit normal ( ULN ) ) , kidney function ( creatinine &lt; 1.5 x ULN ) , know cardiac ejection fraction &gt; = 45 % within past 3 month Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 . 5 ) A negative urine pregnancy test require within 1 week woman childbearing potential prior enrol trial . 6 ) Patient must ability understand requirement study sign informed consent . A sign informed consent patient legally authorize representative require prior enrollment protocol . 7 ) Patient must ability understand requirement study sign informed consent . A sign informed consent patient legally authorize representative require prior enrollment protocol . 1 . Pregnant woman exclude study agent use study potential teratogenic abortifacient effect . Because potential risk adverse event nurse infant secondary treatment mother chemotherapy agent , breastfeed also avoid . 2 . Uncontrolled intercurrent illness include , limited active uncontrolled infection , symptomatic congestive heart failure ( NYHA Class III IV ) , unstable angina pectoris , clinically significant cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 3 . Patient document hypersensitivity component chemotherapy program . 4 . Men woman childbearing potential practice contraception . Women childbearing potential men must agree use contraception prior study entry duration study participation . 5 . Patients history clinically significant venous thromboembolism .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hematologic malignancy</keyword>
	<keyword>Relapsed refractory hematologic malignancy</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Burkitt 's leukemia/lymphoma</keyword>
	<keyword>Prolymphocytic leukemia</keyword>
	<keyword>Biphenotypic acute leukemia</keyword>
	<keyword>Blast-phase chronic myeloid leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>B-cell lymphoma</keyword>
	<keyword>Richter 's transformation chronic lymphocytic leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine arabinosine hydrochloride</keyword>
</DOC>